Anchor Investors Pump in Rs. 1,016 Cr Ahead of Anthem Biosciences IPO Opening on July 14

Anthem Biosciences, a leading contract research and manufacturing organisation (CRDMO), is set to open its ₹3,395 crore initial public offering (IPO) on Monday, July 14. The Bengaluru-based biotech firm has already secured ₹1,016.02 crore from 60 marquee anchor investors, signaling strong institutional interest ahead of its market debut.

₹1,016 Crore Raised via Anchor Book from Global and Domestic Funds

On Friday, July 11, Anthem Biosciences successfully raised ₹1,016.02 crore through its anchor book by allocating 1.78 crore shares at ₹570 apiece, the upper end of its IPO price band. The price band for the IPO has been set between ₹540 and ₹570 per equity share, implying an estimated market capitalization of ₹31,800 crore at the top-end valuation.

The anchor portion attracted robust participation from leading sovereign wealth funds, global pension funds, and mutual funds. Notable anchor investors include:

• Abu Dhabi Investment Authority

• Government Pension Fund Global (Norway)

• Eastspring Investments, Amundi Funds, PineBridge, and Societe Generale

• Optimix Wholesale Global Emerging Markets Share Trust

On the domestic front, ₹604.4 crore of the total anchor book investment came from top Indian mutual fund houses, including:

• HDFC MF, ICICI Prudential AMC, Kotak Mahindra Trustee, Nippon Life India Trustee

• Aditya Birla Sun Life AMC, Axis MF, Franklin Templeton, Mirae Asset, UTI MF, and Quant MF

This diversified institutional participation lends strong credibility to the IPO ahead of the public bidding phase.

Highlights:

• Anchor Book Size: ₹1,016.02 crore

• Anchor Price: ₹570 per share

• Anchor Investors: 60 institutions, including sovereign wealth and mutual funds

• IPO Price Band: ₹540 – ₹570

• Estimated Market Cap: ₹31,800 crore

Read Also: Stock Split on Radar as BEML Board Meet Set for July 21; Share Price in Focus

Anthem Biosciences IPO Details: Offer Size, Dates, and Nature

The Anthem Biosciences IPO opens on July 14 and closes on July 16, with the entire issue being a pure offer-for-sale (OFS) of ₹3,395 crore. Proceeds from the IPO will not go to the company but instead to existing promoters and shareholders looking to pare their holdings.

There is no fresh issue component, meaning the company will not raise new capital through this offering. JM Financial, Citi India, J.P. Morgan India, and Nomura Financial are the book-running lead managers (BRLMs).

Anthem operates as a vertically integrated CRDMO, offering comprehensive services in drug discovery, development, and manufacturing. The company caters to the global pharmaceutical and biotech industries, leveraging its advanced R&D platforms and manufacturing capabilities.

Anthem Biosciences IPO GMP Today Indicates Strong Listing Potential

According to market observers at investorgain.com, the grey market premium (GMP) for Anthem Biosciences IPO today is ₹97, suggesting a strong investor appetite. Based on this GMP, the estimated listing price could be around ₹667 per share, reflecting a 17.02% premium over the upper issue price of ₹570.

The GMP trend over the past 13 sessions has shown consistent strength, with the lowest premium recorded at ₹0 and the highest at ₹107. This upward momentum points toward a potentially robust listing, backed by strong demand and institutional confidence.

GMP Summary:

• IPO GMP Today: ₹97

• Implied Listing Price: ₹667 (17.02% premium)

• GMP Trend: Rising over last 13 sessions

• Maximum GMP Recorded: ₹107

Company Overview: Innovation-Driven CRDMO Model

Anthem Biosciences operates on a contract research, development, and manufacturing model, focused on delivering end-to-end solutions to pharmaceutical and biotech companies worldwide. It is involved in early-stage drug discovery, complex R&D services, and commercial-scale manufacturing of APIs and intermediates.

With a business model that mirrors global CDMO leaders, Anthem is well-positioned to benefit from the increased outsourcing trend in the global life sciences and pharmaceutical space.

Market participants will keenly track the listing performance on July 23, after the closure of the IPO subscription window on July 16.